Perspective · 10 Sep 2026
Conference abstractPublished 24 Oct 2016
Challenges and successes of measuring antigen-specific T cell responses
Cellular Technology Limited, USA; Case Western Reserve University School of Medicine, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Assessing immunogenicity is a challenge in the biopharmaceutical industry, as an increasing number of new drugs and vaccines aim to elicit a response from the cellular components (e.g., T cells) of the immune system. Measurements of antibodies in bodily fluids (e.g., by ELISA) have provided robust and reproducible results for decades and such assays have been validated for monitoring of B-cell immunity. In contrast, measuring T-cell immunity has proven to be more of a challenge, due to the need to test live cells in functional assays ex vivo. While T cells play a critical role in tumor rejection, reliable measurements of antigen-specific T cell responses ex-vivo remain seemingly problematic as typically, T cells occur in very low frequencies in test samples, such as peripheral blood. Therefore, monitoring antigen-specific T cells and their effector functions is critical for the understanding of diseases and for proper assessments of the efficacies of specific cancer immune therapies. In addition, for an assay to reliably measure T-cell functions, it needs to be warranted that the test conditions are such that the function of T cells in vitro remains unimpaired relative to ex vivo. In theory, several techniques are available, including the use of HLA/ peptide tetramers, intra-cellular cytokine staining, ELISA and ELISPOT. In praxis, however, only ELISPOT assays might meet this need, because of the requirement for very high sensitivity to detect the rare antigen specific T cells, the limited number of cells obtainable from patients, the assay’s independence of the HLA genotype of the test subjects, and the ease of performing the assay. Divergent expression profiles of tumor antigens, even within the tumor of a single patient, make it difficult to come up with a general tumor vaccine or to customize immune therapy for an individual patient. Most tumor antigens correspond to normal self-proteins, against which T cell tolerance has been established, either in the thymus or in the immune periphery. However, this negative selection of the auto-antigen- (tumor antigen) specific T cell repertoire is inherently incomplete, being defined by the T cell activation threshold with the density of the nominal antigen and of co-stimulatory molecules exerting synergistic effects. Tumor antigens typically are cryptic auto-antigens and determinant spreading can render cryptic tumor antigens immunogenic, thereby leading to tumor rejection and resulting in protective anti-tumor immunity. Examples of such successful T cell monitoring in tumor models will be presented.
Subjects
Immunology & MicrobiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Clinical and Cellular Immunology.
Commentary · 22 Jul 2026
From Bench to Bedside: Reframing the CXCL13/CXCR5 Axis as a Non-Redundant Organizer of Protective Pulmonary Immunity in COVID-19
Commentary · 17 Jul 2026
CD5L:p40, a third wheel to IL-12 and IL-23 biology?
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Clinical and Cellular Immunology
- SubjectImmunology & Microbiology
- BylineArticles whose byline prints “Magdalena Tary-Lehmann”
